Three Versus Five Years of Adjuvant Imatinib as Treatment of Patients With Operable GIST
Last updated on July 2021Recruitment
- Recruitment Status
- Recruiting
- Estimated Enrollment
- Same as current
Summary
- Conditions
- Sarcoma
- Type
- Interventional
- Phase
- Phase 3
- Design
- Allocation: RandomizedIntervention Model: Parallel AssignmentMasking: None (Open Label)Primary Purpose: Treatment
Participation Requirements
- Age
- Between 18 years and 100 years
- Gender
- Both males and females
Description
The study will accrue patients in several countries in the Europe.
The study will accrue patients in several countries in the Europe.
Tracking Information
- NCT #
- NCT02413736
- Collaborators
- Scandinavian Sarcoma Group
- Investigators
- Principal Investigator: Heikki Joensuu Helsinki University Central Hospital